Articles by James Calloway
Atara Biotherapeutics Surges on FDA Leadership Shift, EBVALLO Review in Focus
Atara Biotherapeutics shares surged 18% Monday following news of an upcoming FDA leadership change, reviving investor hope for a reconsideration of its rejected EBVALLO therapy for a rare blood cancer.
Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.
Unusual Machines Shares Surge on Preliminary 2025 Revenue Doubling
Unusual Machines shares climbed 7% Monday following preliminary results showing 2025 revenue more than doubled to $11.2 million and cash reserves topped $103 million. The drone components maker also reported a widened quarterly operating loss.
W&T Offshore Posts Wider 2025 Loss Amid Revenue Drop, Sees Regulatory Relief
W&T Offshore disclosed a deeper net loss for 2025, with revenue declining to $501.5 million. The company highlighted reduced net debt and potential regulatory relief from proposed offshore financial assurance rules.
Reviva Pharma Enacts Reverse Split to Fend Off Nasdaq Delisting
Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.
uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute
uniQure shares jumped 34% in premarket trading following news that FDA biologics chief Vinay Prasad will depart in April. The move comes amid a regulatory standoff over the company's Huntington's disease gene therapy.
3D Systems Tops Q4 Forecasts, but Bleak Q1 Outlook Raises Doubts
3D Systems reported Q4 revenue of $106.3M, exceeding its forecast, though full-year sales fell 12%. The company anticipates a revenue decline and continued losses for the current quarter.
Palantir Faces Pentagon AI Ban Fallout as Defense Tech Reliance Questioned
Palantir Technologies confronts new risks as the U.S. Pentagon designates AI supplier Anthropic a supply-chain threat, raising concerns over its defense software dependencies. Broader market jitters add to the pressure.
Broadcom's AI Surge Faces Market Test After Strong Outlook
Broadcom's AI revenue jumped 106% to $8.4 billion last quarter, with a new $10.7 billion target set for the current period. The chipmaker's stock will be tested as investors digest its aggressive growth forecast amid broader market declines.
Mesoblast Surges on Ryoncil Sales, Sets $120M Revenue Target
Mesoblast Limited's stock climbed 3% in early U.S. trading following strong first-half results fueled by its newly launched cell therapy Ryoncil. The company has established a fiscal 2026 revenue target of $110-120 million for the product.